Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase...
38 insider purchases on record · latest filing 2026-05-11.
Insiders have also filed 37 sale transactions at CLRB.